What this hub is
Peptide medicine is one of the most promising and most misrepresented areas of modern health. Marketing tends to overstate what compounds can do; skeptics tend to dismiss the field entirely. This library tries to do something harder: explain the actual mechanism, grade the actual evidence, and note the actual regulatory status for each compound — so you arrive at a clinical consultation with a useful foundation.
Semaglutide and tirzepatide are the most clinically validated peptide-class medications in recent pharmacology. RCT evidence shows 15–21% average body-weight reduction and a 20% reduction in major cardiovascular events (SELECT trial, PMID: 37952131). FDA-approved for diabetes and obesity; compounding under 503A now restricted to documented individualized need following shortage resolution.
Read the Full GLP-1 PageCJC-1295/ipamorelin, tesamorelin, and sermorelin modulate growth-hormone signaling. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. CJC-1295 and ipamorelin are not currently offered through YourHealthRx: their nominations were withdrawn and they are not on the FDA 503A bulk drug substances list, so they have no current lawful compounding basis. Sermorelin remains available through partner pharmacies pursuant to patient-specific prescriptions. This card is educational reference only.
Talk to a ClinicianBPC-157 and TB-500 are discussed for musculoskeletal recovery and wound healing. Evidence is predominantly preclinical (animal and in-vitro models) — biologically plausible is not the same as clinically proven. We state this clearly. These substances are not currently offered through YourHealthRx: they are not on the FDA 503A bulk drug substances list and remain under FDA Pharmacy Compounding Advisory Committee (PCAC) review (meeting July 23, 2026). This card is educational reference only.
Talk to a ClinicianGHK-Cu, PT-141 (bremelanotide), KPV, and related compounds span skin, sexual health, and immune modulation. Bremelanotide is FDA-approved for specific indications; the broader class relies on preclinical and early-stage evidence. GHK-Cu (topical) and PT-141 are offered through partner pharmacies; KPV is not currently offered through YourHealthRx — it is not on the FDA 503A bulk drug substances list and remains under FDA PCAC review (July 23, 2026). This card is educational reference only.
Talk to a ClinicianOur editorial standard
Not all evidence is equal. We use a standard hierarchy — and we state it explicitly on every compound page — because conflating an RCT with a rat study is how medical misinformation spreads.
Multi-center randomized controlled trials and systematic meta-analyses represent the highest-quality evidence. GLP-1 receptor agonists (STEP, SURMOUNT, and SELECT trials) carry this designation.
Single-center RCTs, well-designed controlled studies, and dose-escalation trials in humans.
Cohort studies, case-control designs, and retrospective series. Useful for hypothesis generation, but not a substitute for randomized data.
Animal studies (rodent models, swine, equine) and in-vitro mechanistic research. We note this clearly, because biologically plausible is not the same as clinically proven.
FDA approval status, 503A compounding legality, WADA prohibited-substance status, and relevant advisory committee timelines are included on every page and updated when guidance changes.
All content uses “may support,” “evidence suggests,” and “discuss with your clinician” framing. We never write “will cure,” “proven to treat,” or “FDA-approved for” off-label uses. Medical decisions rest with licensed clinicians.
FAQ
Start here if you're new to peptide medicine or want to understand how this hub approaches evidence and safety.
Peptides are short chains of amino acids that act as biological signaling molecules. They regulate hormone secretion, appetite, tissue repair, inflammation, and immune function. In telehealth medicine, synthetic peptides mimic or amplify these natural signals in targeted ways. The body naturally produces thousands of peptides; therapeutic peptides are synthetic versions designed to produce specific clinical effects.
Yes — but the approved indications vary significantly by compound. Semaglutide and tirzepatide (GLP-1 receptor agonists) are FDA-approved for type 2 diabetes and obesity management. Most other peptide compounds in the wellness space are not FDA-approved for any indication, and their availability depends on the FDA 503A bulk drug substances list and state-level rules. Each compound page lists regulatory status explicitly.
You don't determine this from reading a library — a licensed clinician does, after reviewing your complete medical history, current medications, relevant lab values, and health goals. This hub gives you a science-literate foundation for that conversation. Prescriptions are issued at the sole discretion of the prescribing clinician.
Compounded medications are prepared by licensed pharmacies for individual patients under a specific prescription. They are regulated by state pharmacy boards and must meet USP sterility and quality standards, but they do not go through FDA's pre-market drug approval process. Compounding legality varies by compound — GLP-1 agonists, for example, have significant restrictions as of 2026 following shortage resolution.
Clinical trials are expensive — typically $50M to $1B+ for a full Phase 2/3 program. Peptides that occur naturally or cannot be broadly patented offer limited commercial incentive for pharmaceutical companies to fund trials. This creates a research gap: biologically compelling compounds with extensive preclinical evidence but no human RCT validation. We note this gap honestly for every compound where it applies.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) evaluates whether specific substances should be added to or removed from the 503A bulk drug substances list — the list of substances licensed compounding pharmacies are permitted to use. Inclusion on the 503A list is one of the gating factors for whether a clinician can lawfully prescribe a compounded peptide preparation. We update this library following each PCAC meeting that affects peptide compounding.
Informational only. Content on this page is for informational purposes and does not constitute medical advice. All prescriptions are issued at the sole discretion of the prescribing clinician. Peptide compounds are prescribed for licensed therapeutic indications only. Not all compounds are available in all states. Results vary.
Ready to talk to a clinician?
Start your intake and connect with a licensed clinician who can review whether a peptide protocol aligns with your health history and goals.
